Publicaciones en colaboración con investigadores/as de University of Rome Tor Vergata (55)

2023

  1. Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia

    British Journal of Haematology, Vol. 200, Núm. 2, pp. 170-174

2022

  1. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x)

    Nature Communications

  2. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

    Leukemia, Vol. 36, Núm. 1, pp. 90-99

2021

  1. Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants

    Blood Cancer Journal

  2. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

    Nature Communications, Vol. 12, Núm. 1

  3. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

    Leukemia, Vol. 35, Núm. 9, pp. 2539-2551

2020

  1. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

    Blood, Vol. 135, Núm. 5, pp. 371-380

  2. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: A subanalysis from the RATIFY trial

    Blood Advances, Vol. 4, Núm. 19, pp. 4945-4954

  3. NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia

    Scientific Reports, Vol. 10, Núm. 1

  4. Obesity is a risk factor for acute promyelocytic leukemia: Evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism

    Haematologica, Vol. 105, Núm. 6, pp. 1559-1566

  5. Reduced SLIT2 is associated with increased cell proliferation and arsenic trioxide resistance in acute promyelocytic Leukemia

    Cancers, Vol. 12, Núm. 11, pp. 1-16

2019

  1. Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia

    Blood, Vol. 134, Núm. 12, pp. 951-959

  2. Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European LeukemiaNet

    Blood, Vol. 133, Núm. 15, pp. 1630-1643

2018

  1. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes

    Haematologica

  2. Molecular remission as a therapeutic objective in acute promyelocytic leukemia

    Leukemia, Vol. 32, Núm. 8, pp. 1671-1678

  3. The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia

    British Journal of Haematology

2017

  1. Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia

    Blood Advances, Vol. 1, Núm. 21, pp. 1807-1814

  2. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Blood, Vol. 129, Núm. 4, pp. 424-447

  3. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation

    New England Journal of Medicine, Vol. 377, Núm. 5, pp. 454-464

  4. Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy

    Annals of Hematology, Vol. 96, Núm. 9, pp. 1449-1456